• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Adamas to Announce Second Quarter Financial Results and Host Conference Call on August 9, 2021

    8/2/21 4:02:00 PM ET
    $ADMS
    Major Pharmaceuticals
    Health Care
    Get the next $ADMS alert in real time by email

    Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) today announced that the company will report second quarter 2021 financial results on Monday, August 9, after market close. Subsequently, Adamas' management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.

    Investor Conference Call and Webcast

    The conference call can be accessed by dialing 1-877-407-9716 for participants in the U.S. or Canada and 1-201-493-6779 for international callers. All callers must provide the following Conference ID: 13720109. The webcast can be accessed live via the investor section of the Adamas website at https://ir.adamaspharma.com/events-presentations and will be available for replay for approximately 30 days.

    About Adamas Pharmaceuticals, Inc.

    At Adamas our vision is clear – to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. For more information, please visit www.adamaspharma.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20210802005659/en/

    Get the next $ADMS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ADMS

    DatePrice TargetRatingAnalyst
    11/17/2021$8.50Outperform → Market Perform
    Northland Capital Markets
    10/12/2021Market Outperform → Market Perform
    JMP Securities
    10/12/2021$7.00 → $8.00Overweight → Neutral
    Piper Sandler
    10/12/2021$10.00 → $9.10Buy → Neutral
    HC Wainwright & Co.
    10/11/2021Outperform → Market Perform
    William Blair
    More analyst ratings

    $ADMS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals

      ROCKVILLE, Md., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) today announced that it has successfully completed its previously announced acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS). "Adamas fits squarely within our corporate development strategy, adding a late-stage commercial product with significant revenue," said Jack Khattar, President and CEO of Supernus Pharmaceuticals. "In addition, the acquisition adds a new growth catalyst, diversifies our revenue base and cash flow, and is expected to be significantly accretive in 2022." Compelling Strategic Rationale Strengthens Parkinson's disease portfolio with GOCOVRI® (amantadine) extended r

      11/24/21 9:12:51 AM ET
      $ADMS
      $SUPN
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Adamas Pharmaceuticals Tender Offer

      ROCKVILLE, Md., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Supernus' proposed acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) expired at 11:59 p.m. on November 22, 2021. On October 21, 2021, Supernus and Adamas filed the Premerger Notification and Report Forms required under the HSR Act with the Federal Trade Commission and the Antitrust Division of the U.S. Department of Justice. The expiration of the HSR Act waiting period satisfies one of the conditions to consummate the Offer (as defined below). The Off

      11/23/21 8:00:00 AM ET
      $ADMS
      $SUPN
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product Portfolio

      Acquisition of two marketed products diversifies and accelerates revenue and cash flowExpected to be significantly accretive in 2022Potential synergies of $60 million to $80 million in year one due to strong overlap with existing infrastructureTotal consideration up to $9.10 per share. Upfront cash payment of $8.10 per share with fully diluted equity value of approximately $400 million, plus $1.00 contingent value right based on net sales of GOCOVRI®Conference call and webcast today at 8:30 a.m. ET to discuss the transaction ROCKVILLE, Md. and EMERYVILLE, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) and Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS),

      10/11/21 6:30:00 AM ET
      $ADMS
      $SUPN
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $ADMS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Bigham Michael closing all direct ownership in the company

      4 - Adamas Pharmaceuticals Inc (0001328143) (Issuer)

      11/24/21 4:11:37 PM ET
      $ADMS
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: Mahoney David L closing all direct ownership in the company

      4 - Adamas Pharmaceuticals Inc (0001328143) (Issuer)

      11/24/21 4:11:16 PM ET
      $ADMS
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: Prentiss Christopher B was granted 18,750 shares, closing all direct ownership in the company

      4 - Adamas Pharmaceuticals Inc (0001328143) (Issuer)

      11/24/21 4:10:18 PM ET
      $ADMS
      Major Pharmaceuticals
      Health Care

    $ADMS
    SEC Filings

    See more
    • SEC Form 15-12B filed by Adamas Pharmaceuticals, Inc.

      15-12B - Adamas Pharmaceuticals Inc (0001328143) (Filer)

      12/6/21 5:25:20 PM ET
      $ADMS
      Major Pharmaceuticals
      Health Care
    • SEC Form EFFECT filed by Adamas Pharmaceuticals, Inc.

      EFFECT - Adamas Pharmaceuticals Inc (0001328143) (Filer)

      12/2/21 12:15:24 AM ET
      $ADMS
      Major Pharmaceuticals
      Health Care
    • SEC Form S-8 POS filed by Adamas Pharmaceuticals, Inc.

      S-8 POS - Adamas Pharmaceuticals Inc (0001328143) (Filer)

      11/24/21 11:53:45 AM ET
      $ADMS
      Major Pharmaceuticals
      Health Care

    $ADMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Adamas Pharmaceuticals downgraded by Northland Capital Markets with a new price target

      Northland Capital Markets downgraded Adamas Pharmaceuticals from Outperform to Market Perform and set a new price target of $8.50

      11/17/21 7:40:51 AM ET
      $ADMS
      Major Pharmaceuticals
      Health Care
    • Adamas Pharmaceuticals downgraded by JMP Securities

      JMP Securities downgraded Adamas Pharmaceuticals from Market Outperform to Market Perform

      10/12/21 6:50:59 AM ET
      $ADMS
      Major Pharmaceuticals
      Health Care
    • Adamas Pharmaceuticals downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Adamas Pharmaceuticals from Overweight to Neutral and set a new price target of $8.00 from $7.00 previously

      10/12/21 6:47:58 AM ET
      $ADMS
      Major Pharmaceuticals
      Health Care

    $ADMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Adamas Pharmaceuticals, Inc. (Amendment)

      SC 13G/A - Adamas Pharmaceuticals Inc (0001328143) (Subject)

      12/10/21 8:52:22 AM ET
      $ADMS
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed by Adamas Pharmaceuticals, Inc. (Amendment)

      SC 13G/A - Adamas Pharmaceuticals Inc (0001328143) (Subject)

      10/20/21 3:42:52 PM ET
      $ADMS
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13D filed by Adamas Pharmaceuticals, Inc.

      SC 13D - Adamas Pharmaceuticals Inc (0001328143) (Subject)

      10/19/21 4:26:46 PM ET
      $ADMS
      Major Pharmaceuticals
      Health Care

    $ADMS
    Financials

    Live finance-specific insights

    See more
    • Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals

      ROCKVILLE, Md., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) today announced that it has successfully completed its previously announced acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS). "Adamas fits squarely within our corporate development strategy, adding a late-stage commercial product with significant revenue," said Jack Khattar, President and CEO of Supernus Pharmaceuticals. "In addition, the acquisition adds a new growth catalyst, diversifies our revenue base and cash flow, and is expected to be significantly accretive in 2022." Compelling Strategic Rationale Strengthens Parkinson's disease portfolio with GOCOVRI® (amantadine) extended r

      11/24/21 9:12:51 AM ET
      $ADMS
      $SUPN
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product Portfolio

      Acquisition of two marketed products diversifies and accelerates revenue and cash flowExpected to be significantly accretive in 2022Potential synergies of $60 million to $80 million in year one due to strong overlap with existing infrastructureTotal consideration up to $9.10 per share. Upfront cash payment of $8.10 per share with fully diluted equity value of approximately $400 million, plus $1.00 contingent value right based on net sales of GOCOVRI®Conference call and webcast today at 8:30 a.m. ET to discuss the transaction ROCKVILLE, Md. and EMERYVILLE, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) and Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS),

      10/11/21 6:30:00 AM ET
      $ADMS
      $SUPN
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Adamas Reports Second Quarter 2021 Financial Results

      Second quarter 2021 total revenues of $22.0 million, a 17% increase over second quarter 2020 GOCOVRI new paid prescriptions of 730, a 97% increase over second quarter 2020 Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today reported financial results for the second quarter ended June 30, 2021, and recent corporate highlights. "We delivered a strong performance in the second quarter, with a robust increase in demand set to fuel future growth," said Neil F. McFarlane, Chief Executive Officer. "We remain on track to achieve our 2021 goals as we navigate the

      8/9/21 4:01:00 PM ET
      $ADMS
      Major Pharmaceuticals
      Health Care